BioSpace News Archive

Madrigal Pharmaceuticals, Inc. today announced five health economics abstracts being presented at the NASH-TAG Conference, taking place from January 4-6, 2024 in Park City, Utah.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has achieved technological proof of concept for DARE-LARC1 and the underlying innovative drug delivery platform designed to store and precisely deliver therapeutic doses over months or years through a single device.

Peak Bio, Inc. (“Peak Bio” or the “Company”) (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin Analogs” by The United States Patent and Trademark Office (USPTO).

Lisata Therapeutics, Inc. today announced the publication of a case report detailing a complete response in a patient with metastatic gastroesophageal adenocarcinoma patient treated with LSTA1 in combination with the standard-of-care therapy in Oncology & Cancer Case Reports Journal on December 30, 2023.

ProPhase Labs, Inc. today reported that Jed Latkin, a long-time operations and finance expert, has accepted the role as COO of the parent company.

Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 11:15 a.m. PT (2:15 p.m. ET) in the Borgia Room at The Westin St. Francis Hotel in San Francisco.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final draft guidance recommending Evkeeza® (evinacumab) to NHS England.

Claris Bio unveiled the company and its lead program, with a total of $57 million invested from Series A investors Novo Holdings A/S, RA Capital and Mass General Brigham Ventures and recent investor, Janus Henderson Investors.

Pfizer Canada ULC announces today the Health Canada approval of ABRYSVOTM, its bivalent Respiratory Syncytial Virus (RSV) vaccine.

AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2023 financial results on Friday, February 2, 2024, before the market opens.